IL117807A - Use of a history of 3,1-Dihydro-1 (phenylalkyl) - 2H-imidazole - 2 On for the preparation of drugs, such new derivatives, the process for their preparation and the pharmaceutical preparations containing them - Google Patents

Use of a history of 3,1-Dihydro-1 (phenylalkyl) - 2H-imidazole - 2 On for the preparation of drugs, such new derivatives, the process for their preparation and the pharmaceutical preparations containing them

Info

Publication number
IL117807A
IL117807A IL11780796A IL11780796A IL117807A IL 117807 A IL117807 A IL 117807A IL 11780796 A IL11780796 A IL 11780796A IL 11780796 A IL11780796 A IL 11780796A IL 117807 A IL117807 A IL 117807A
Authority
IL
Israel
Prior art keywords
substituted
alkyl
formula
aryl
hydrogen
Prior art date
Application number
IL11780796A
Other languages
English (en)
Hebrew (he)
Other versions
IL117807A0 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL117807A0 publication Critical patent/IL117807A0/xx
Publication of IL117807A publication Critical patent/IL117807A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL11780796A 1995-04-06 1996-04-03 Use of a history of 3,1-Dihydro-1 (phenylalkyl) - 2H-imidazole - 2 On for the preparation of drugs, such new derivatives, the process for their preparation and the pharmaceutical preparations containing them IL117807A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200868 1995-04-06
EP95202898 1995-10-26

Publications (2)

Publication Number Publication Date
IL117807A0 IL117807A0 (en) 1996-08-04
IL117807A true IL117807A (en) 2001-06-14

Family

ID=26139205

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11780796A IL117807A (en) 1995-04-06 1996-04-03 Use of a history of 3,1-Dihydro-1 (phenylalkyl) - 2H-imidazole - 2 On for the preparation of drugs, such new derivatives, the process for their preparation and the pharmaceutical preparations containing them

Country Status (27)

Country Link
US (2) US5994376A (hu)
EP (1) EP0819122B1 (hu)
JP (1) JP4562101B2 (hu)
KR (1) KR100406628B1 (hu)
CN (1) CN1068591C (hu)
AR (1) AR002732A1 (hu)
AT (1) ATE214052T1 (hu)
AU (1) AU702947B2 (hu)
CA (1) CA2216653C (hu)
CY (1) CY2328B1 (hu)
CZ (1) CZ293127B6 (hu)
DE (1) DE69619661T2 (hu)
DK (1) DK0819122T3 (hu)
ES (1) ES2174064T3 (hu)
HK (1) HK1007880A1 (hu)
HR (1) HRP960155A2 (hu)
HU (1) HU223324B1 (hu)
IL (1) IL117807A (hu)
MX (1) MX9707652A (hu)
MY (1) MY119254A (hu)
NO (1) NO314339B1 (hu)
NZ (1) NZ304877A (hu)
PL (1) PL187375B1 (hu)
PT (1) PT819122E (hu)
SI (1) SI0819122T1 (hu)
TW (1) TW332201B (hu)
WO (1) WO1996031485A1 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
SK285878B6 (sk) * 1996-10-02 2007-10-04 Janssen Pharmaceutica N. V. Derivát 2-kyaniminoimidazolu, prostriedok obsahujúci tento derivát, spôsob prípravy tohto prostriedku, uvedený derivát na použitie ako liečivo, použitie tohto derivátu na prípravu liečiva a spôsob prípravy tohto derivátu
NZ501627A (en) 1997-07-10 2002-02-01 Janssen Pharmaceutica Nv 3,5-dioxo-2(3H)-triazine derivatives substituted by 4-(phenylmethyl)phenyl useful as IL-5 inhibitors
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
SK284468B6 (sk) * 1998-04-01 2005-04-01 Janssen Pharmaceutica N. V. Pyridínový derivát, spôsob jeho prípravy a použitie, kompozícia s jeho obsahom a spôsob jej prípravy
CA2328250A1 (en) * 1998-04-14 1999-10-21 Cornelia Jutta Forster Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
US6172118B1 (en) * 1998-04-14 2001-01-09 Smithkline Beecham Corporation Compounds
ES2198980T3 (es) * 1998-11-23 2004-02-01 Janssen Pharmaceutica N.V. Derivados de 6-azauralico inhibidores de il-5.
ATE365723T1 (de) 1998-12-18 2007-07-15 Janssen Pharmaceutica Nv Il-5 hemmende 6-uracilderivate
AU2001290884B2 (en) * 2000-09-13 2005-12-15 Merck & Co., Inc. Alpha V integrin receptor antagonists
CA2447618A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for regenerative treatment of cartilage disease
MXPA03010679A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
US6706739B2 (en) * 2001-08-21 2004-03-16 National Health Research Institute Imidazolidinone compounds
SE0200667D0 (sv) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
GB0326407D0 (en) * 2003-11-12 2003-12-17 Glaxo Group Ltd Chemical compounds
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
CN1997367B (zh) * 2004-07-05 2010-11-24 同和药品株式会社 预防和治疗过敏性炎症的组合物
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
US7390772B2 (en) * 2006-05-18 2008-06-24 International Flavor & Fragrances Inc. 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations
WO2008157425A2 (en) * 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
JP2018513153A (ja) 2015-04-24 2018-05-24 オメロス コーポレーション Ｐｄｅ１０インヒビターならびに関連する組成物および方法
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL285394A (hu) * 1961-11-17
US3184060A (en) 1963-02-13 1965-05-18 Owens Illinois Glass Co Packaging tacky latex emulsion paints in containers manufactured from polyolefinic maerials
CA2095429A1 (en) * 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
DE69332762T2 (de) * 1992-12-02 2003-08-14 Pfizer Inc., New York Cathecoldiether als selektive pde iv hemmungsmittel
TW263495B (hu) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
PL322654A1 (en) 1998-02-16
NO314339B1 (no) 2003-03-10
EP0819122A1 (en) 1998-01-21
DK0819122T3 (da) 2002-07-01
PT819122E (pt) 2002-08-30
CN1181072A (zh) 1998-05-06
EP0819122B1 (en) 2002-03-06
AU702947B2 (en) 1999-03-11
NZ304877A (en) 1999-06-29
WO1996031485A1 (en) 1996-10-10
HUP9801575A3 (en) 1999-03-01
KR100406628B1 (ko) 2004-05-31
US5994376A (en) 1999-11-30
JP4562101B2 (ja) 2010-10-13
HUP9801575A2 (hu) 1999-01-28
DE69619661T2 (de) 2002-10-31
DE69619661D1 (de) 2002-04-11
PL187375B1 (pl) 2004-06-30
CN1068591C (zh) 2001-07-18
ES2174064T3 (es) 2002-11-01
KR19980703449A (ko) 1998-11-05
CA2216653A1 (en) 1996-10-10
AR002732A1 (es) 1998-04-29
HU223324B1 (hu) 2004-06-28
IL117807A0 (en) 1996-08-04
NO974602D0 (no) 1997-10-06
HK1007880A1 (en) 1999-04-30
HRP960155A2 (en) 1997-10-31
MX9707652A (es) 1997-11-29
TW332201B (en) 1998-05-21
CY2328B1 (en) 2004-02-06
JPH11503136A (ja) 1999-03-23
CA2216653C (en) 2009-05-26
NO974602L (no) 1997-10-06
CZ293127B6 (cs) 2004-02-18
CZ314997A3 (cs) 1998-12-16
US6403805B1 (en) 2002-06-11
US20020068830A1 (en) 2002-06-06
MY119254A (en) 2005-04-30
AU5275596A (en) 1996-10-23
SI0819122T1 (en) 2002-06-30
ATE214052T1 (de) 2002-03-15

Similar Documents

Publication Publication Date Title
US6403805B1 (en) 1,3-dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatves
EP0934280B1 (en) Pde iv inhibiting 2-cyanoiminoimidazole derivatives
EP0819123B1 (en) 1,3-dihydro-1-(phenylalkenyl)-2h-imidazol-2-one derivatives having pde iv and cytokine inhibiting activity
EP0832071B1 (en) 1,3-dihydro-2h-imidazol-2-one derivatives having pde iv and cytokinin inhibiting activity
US6656959B1 (en) PDE IV inhibiting pyridine derivatives
AU697390C (en) 1,3-dihydro-2h-imidazol-2-one derivatives having PDE IV and cytokinin inhibiting activity

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired